CD28 and gastric cancer: Previous results in gastric cancer cultures demonstrated that the effect of the PD-1 inhibitor nivolumab can be enhanced when combined with immune activators (e.g., CD3/CD28 T-lymphocyte activator ImmunoCultTM), resulting in similar effect sizes to those found in the present study [51].